TrialCancer science2022

Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.

Tadahiro Shoji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.